STRUCTURE BASED DESIGN OF NOVEL INTERLEUKIN-5 RECEPTOR

Information

  • Research Project
  • 6510985
  • ApplicationId
    6510985
  • Core Project Number
    R44AI045249
  • Full Project Number
    5R44AI045249-03
  • Serial Number
    45249
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 25 years ago
  • Project End Date
    5/31/2004 - 20 years ago
  • Program Officer Name
    PROGRAIS, LAWRENCE J.
  • Budget Start Date
    6/1/2002 - 22 years ago
  • Budget End Date
    5/31/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    3
  • Suffix
  • Award Notice Date
    5/30/2002 - 22 years ago

STRUCTURE BASED DESIGN OF NOVEL INTERLEUKIN-5 RECEPTOR

DESCRIPTION: IL-5 is an essential cytokine for the maturation of eosinophil precursors to eosinophils, and it is those eosinophils that have been found to correlate with the severity of the late asthmatic reaction. Thus, design of IL-5 receptor antagonists that block pulmonary eosinophil disorders and present a new approach to treating allergic asthma. In Phase I, we used SBI technology to compute a 3-D dynamic model from the crystal structure of IL-5 and construct pharmacophore templates to screen large scale compound libraries in order to identify potential inhibitors of IL-5 action. Three compounds showing Ki greater than 10 uM in an IL-5 receptor plate assays were obtained. The goal of Phase II is to perform computationally guided synthetic optimizations of active lead compounds identified in Phase I and to discover selective and potent drug candidates active in a murine model for allergic asthma. The long term goal of this project is to develop at least one non-peptide IL-5 receptor antagonist as a potential anti-asthmatic and anti-allergic agent. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    324794
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:324794\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CENGENT THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921271811
  • Organization District
    UNITED STATES